Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 10, 2017 Filed Oct 12, 2017 19:31 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 12,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038519 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,686 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 13:44 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 204.266 | $0.00 Strike: $116.27 | $0.00 |
DisclosureSEC source: 0000911916-17-000239 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070.554 Underlying: Common Stock · 204.266 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 102.133 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 102.133 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 7.449 phantom stock units accrued on July 28, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:18 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 27,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032786 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,741 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Includes 91.28 shares of ResMed stock purchased on April 28,2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:52 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 184.954 | $0.00 Strike: $128.41 | $0.00 |
DisclosureSEC source: 0000911916-17-000211 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,858.839 Underlying: Common Stock · 184.954 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 92.477 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 92.477 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,067.85 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-17-000175 · edgar.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,375.497 Underlying: Common Stock · 1,067.85 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $121.74 | $0.00 |
DisclosureSEC source: 0000911916-17-000175 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,673.885 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F4 · balance_after: Includes 6.417 phantom stock units accrued on April 28, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 19:10 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 195.49 | $0.00 Strike: $121.49 | $0.00 |
DisclosureSEC source: 0000911916-17-000147 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,167.468 Underlying: Common Stock · 195.49 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 97.745 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 97.745 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 5.630 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 20:48 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 229.713 | $0.00 Strike: $103.39 | $0.00 |
DisclosureSEC source: 0000911916-17-000010 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966.348 Underlying: Common Stock · 229.713 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 114.856 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 114.856 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 5.006 phantom stock units accrued on October 28, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 16:15 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 139,665 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087167 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,665 Underlying: ResMed Common Stock · 139,665 shares Expires 2023-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2017, 2018 and 2019. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:50 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 8,518 | $59.85 | $509,802.30 |
DisclosureSEC source: 0001140361-16-086061 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,450 F4 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:50 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 8,685 | $59.85 | $519,797.25 |
DisclosureSEC source: 0001140361-16-086061 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,968 F3 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:50 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 6,469 | $59.85 | $387,169.65 |
DisclosureSEC source: 0001140361-16-086061 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,653 F1 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/13/2013. F2 · balance_after: Includes 316 shares of ResMed stock purchased on 10/31/2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 19:49 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,975 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-082981 · doc1.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: ResMed Commmon Stock · 5,975 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 19:49 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,975 | $64.25 | $383,869.85 |
DisclosureSEC source: 0001140361-16-082981 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,806 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.15 to $64.43. The price reported above reflects the weighted average sale price. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 19:49 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,975 | $33.70 | $201,357.50 |
DisclosureSEC source: 0001140361-16-082981 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:22 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 183.582 | $0.00 Strike: $129.37 | $0.00 |
DisclosureSEC source: 0000911916-16-000668 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,731.629 Underlying: Common Stock · 183.582 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 91.791 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 91.791 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 4.349 phantom stock units accrued on July 29, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 15, 2016 Filed Sep 17, 2016 01:15 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,975 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-080106 · doc1.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,275 Underlying: ResMed Commmon Stock · 5,975 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| September 15, 2016 Filed Sep 17, 2016 01:15 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,975 | $64.84 | $387,419.00 |
DisclosureSEC source: 0001140361-16-080106 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,806 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2016 Filed Sep 17, 2016 01:15 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,975 | $33.70 | $201,357.50 |
DisclosureSEC source: 0001140361-16-080106 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.